Pitt Pediatrics congratulates the following faculty on their receipt of new grants during the fourth quarter of fiscal year 2021:
NIH and Other Federal
John F. Alcorn, PhD
Division of Pulmonology
Influenza A Inhibits TH17 Host Defense Against Bacterial Pneumonia
National Institutes of Health, 2R01HL107380-10A1
2021-2025
Kelly M. Bailey, MD, PhD
Division of Hematology-Oncology
DNA Damage and Immunogenicity in Ewing Sarcoma
National Institutes of Health, 1K08CA252178-01A1
2021-2026
Carlton M. Bates, MD and Sunder Sims-Lucas, PhD
Division of Nephrology
The University of Pittsburgh Summer Research Internship Program kidney workshop (SRIP-Kid)
National Institutes of Health, 1R25DK119180-01A1
2021-2026
Juan C. Celedón, MD, DrPH
Division of Pulmonology
Nasal epithelial epigenomics and transcriptomics and asthma in Hispanic adults
National Institutes of Health, 1R01HL152475-01A1
2021-2026
Arjumand Ghazi, PhD
Division of Gastroenterology, Hepatology, and Nutrition
Role of the transcription elongation and splicing factor TCER-1 in repressing immunity and promoting fertility
National Institutes of Health, 1R56AG066682-01A1
2021-2022
Eric S. Goetzman, PhD
Division of Genetic and Genomic Medicine
Regulation of Peroxisomal Metabolism by Lysine Acylation
National Institutes of Health, 2R01DK090242-11
2021-2026
Brydie Ryan Huckestein, BS
Division of Pulmonology
Targeting metabolism to improve outcomes following severe influenza infection
National Institutes of Health, F31HL158002
2021-2024
Melissa Eileen Kane, PhD
Division of Infectious Diseases
Inhibition of lentiviral nuclear import pathways by Mx2
National Institutes of Health, 1R01AI162172-01A1
2021-2026
Mioara D. Manole, MD, FAAP
Division of Emergency Medicine
Targeting vascular contractile cells in capillary stasis after cardiac arrest
National Institutes of Health, 1R21NS121501-01
2021-2023
Amanda C. Poholek, PhD
Division of Rheumatology
Lung-specific expression and function of Blimp-1 in T cells impacting allergic asthma
National Institutes of Health, 1R01AI153104-01A1
2021-2026
Amanda C. Poholek, PhD
Division of Rheumatology
Tissue-specific mediators of allergen-driven type 2 inflammation
National Institutes of Health, 1R21AI156093-01A1
2021-2023
Anne-Marie Rick, MD, MPH
Division of General Academic Pediatrics
Infant Protection from Influenza through Maternal Influenza Immunization
National Institutes of Health, 1K23AI159399-01
2021-2026
Other
Silva Arslanian, MD
Center for Pediatric Research in Obesity and Metabolism
Novo Nordisk Pharmaceuticals, Inc.
Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
2021-2023
Aimee B. Biller, MD
Division of General Academic Pediatrics
National Center for Advancing Translational Science
University of Pittsburgh Clinical and Translational Science Institute
2021-2026
Catalina Cleves-Bayon, MD
Division of Neurology and Child Development Unit
Eli Lilly
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
2021-2023
Stacey Engster, MD, MS
Division of General Academic Pediatrics
National Institutes of Health
University of Pittsburgh Clinical and Translational Science Institute
2021-2022
Catherine S. Forster, MD, MS, FAAP
Paul C. Gaffney Division of Pediatric Hospital Medicine
Children's Hospital of Los Angeles
Improving diagnosis and management of pediatric-associated respiratory infections
2021-2023
Traci M. Kazmerski, MD, MS
Division of Allergy and Immunology
Cystic Fibrosis Foundation
Menopause and Cystic Fibrosis
2021-2022
Eric Koppes, PhD
Division of Genetic and Genomic Medicine
Oregon Health and Science University
Molecular and biochemical characterization of a HepG2 model of Phenylketonuria and its potential use in personalized preclinical studies
2021-2022
Peter C. Lucas, MD, PhD
Division of Hematology-Oncology
National Institutes of Health
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
2021-2026
Peter C. Lucas, MD, PhD
Division of Hematology-Oncology
National Institutes of Health
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
2021-2026
Julia C. Meade, MD
Division of Hematology-Oncology
SpringWorks Therapeutics
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
2021-2023
Elizabeth Miller, MD, PhD, FSAHM
Division of Adolescent and Young Adult Medicine
National Center for Advancing Translational Science
University of Pittsburgh Clinical and Translational Science Institute
2021-2026
Damara Ortiz, MD
Division of Genetic and Genomic Medicine
Avrobio
An Adaptive, Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 For Subjects with Type 1 Gaucher Disease
2021-2023
Anne-Marie Rick, MD, MPH
Division of General Academic Pediatrics
National Institutes of Health
University of Pittsburgh Clinical and Translational Science Institute
2021-2022
James E. Squires, MD, MS
Division of Gastroenterology, Hepatology, and Nutrition
Albireo AB
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT) PED-20-023
2021-2023
Jerry Vockley, MD, PhD, FACMG
Division of Genetic and Genomic Medicine
Kriya Therapeutics, Inc.
AAV gene therapy of VLCAD deficiency
2021-2023
Jerry Vockley, MD, PhD, FACMG
Division of Genetic and Genomic Medicine
Kriya Therapeutics, Inc.
Novel mouse models to assess AAV gene therapy of VLCAD deficiency
2021-2023
Jerry Vockley, MD, PhD, FACMG
Division of Genetic and Genomic Medicine
Homology Medicines, Inc.
A Prospective Study Investigating the Natural History of Adults with Phenylketonuria (PKU) due to Phenylalanine Hydroxylase Deficiency
2021-2023
Selma Feldman Witchel, MD
Division of Endocrinology
Neurocrine Biosciences, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
2021-2023